Cargando…
Oligometastatic Prostate Cancer
The mainstay of treatment for men with three or fewer non-castrate metastatic lesions outside of the prostate remains morbid palliative androgen deprivation therapy. We believe there is now a significant body of retrospective literature to suggest a survival benefit if these men have radical treatme...
Autores principales: | Stevens, Daniel J., Sooriakumaran, Prasanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083765/ https://www.ncbi.nlm.nih.gov/pubmed/27787754 http://dx.doi.org/10.1007/s11864-016-0439-8 |
Ejemplares similares
-
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
por: El-Taji, Omar M. S., et al.
Publicado: (2016) -
The Value of Phenotypic Precision Medicine in Prostate Cancer
por: Hawkey, Nathan M, et al.
Publicado: (2022) -
The Utility of Molecular Imaging in Prostate Cancer
por: Leiblich, Aaron, et al.
Publicado: (2016) -
Rational Second-Generation Antiandrogen Use in Prostate Cancer
por: Orme, Jacob J, et al.
Publicado: (2022) -
Results of a Prospective Dose Escalation Study of Linear Accelerator–Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer
por: Eade, Thomas, et al.
Publicado: (2019)